Literature DB >> 3133397

Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3.

M E Rothenberg1, W F Owen, D S Silberstein, J Woods, R J Soberman, K F Austen, R L Stevens.   

Abstract

Human eosinophils were cultured in the presence of recombinant human IL-3 for up to 14 d and their biochemical, functional, and density properties were assessed. After 3 d of culture in 10 pM IL-3, eosinophils had a viability of 70% compared with only 10% in enriched medium alone. Neither IL-1 alpha, IL-2, IL-4, tumor necrosis factor, basic fibroblast growth factor, nor platelet-derived growth factor maintained eosinophil viability. The 7- and 14-d survival of the cultured eosinophils was 55 and 53%, respectively. No other cell type, including neutrophils, was present after culture. After 7 d of culture, the normodense eosinophils were converted to hypodense cells as assessed by density centrifugation. Eosinophils exposed to 1,000 pM IL-3 for 30 min or cultured in 10 pM IL-3 for 7 d generated approximately threefold more leukotriene C4 (LTC4) in response to calcium ionophore than freshly isolated cells. Furthermore, whereas freshly isolated eosinophils killed only 14% of the antibody-coated Schistosoma mansoni larvae, these eosinophils killed 54% of the larvae when exposed to 100 pM IL-3. The enhanced helminth cytotoxicity was maintained for 7 d when eosinophils were cultured in the presence of both 10 pM IL-3 and 3T3 fibroblasts, but not when eosinophils were cultured in the presence of IL-3 alone. IL-3 thus maintains the viability of eosinophils in vitro, augments the calcium ionophore-induced generation of LTC4, enhances cytotoxicity against antibody-sensitized helminths, and induces the eosinophils to become hypodense cells. These phenotypic changes in the eosinophil may be advantageous to host defense against helminthic infections but may be disadvantageous in conditions such as allergic disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133397      PMCID: PMC442652          DOI: 10.1172/JCI113547

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni.

Authors:  M A Vadas; J R David; A Butterworth; N T Pisani; T A Siongok
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

2.  Maturation in vivo of Schistosoma mansoni schistosomula after culture in vitro with granulocytes and antibody.

Authors:  A Dessein; A E Butterworth; M A Vadas; J R David
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

3.  Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils.

Authors:  J C Gasson; R H Weisbart; S E Kaufman; S C Clark; R M Hewick; G G Wong; D W Golde
Journal:  Science       Date:  1984-12-14       Impact factor: 47.728

4.  Heterogeneity of human eosinophils. II. Variability of respiratory burst activity related to cell density.

Authors:  L Prin; J Charon; M Capron; P Gosset; H Taelman; A B Tonnel; A Capron
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

5.  Human eosinophils and parasitic diseases. II. Characterization of two cell fractions isolated at different densities.

Authors:  C De Simone; G Donneli; D Meli; F Rosati; F Sorice
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

6.  Heterogeneity of human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia.

Authors:  L Prin; M Capron; A B Tonnel; O Bletry; A Capron
Journal:  Int Arch Allergy Appl Immunol       Date:  1983

7.  Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan.

Authors:  E Razin; J N Ihle; D Seldin; J M Mencia-Huerta; H R Katz; P A LeBlanc; A Hein; J P Caulfield; K F Austen; R L Stevens
Journal:  J Immunol       Date:  1984-03       Impact factor: 5.422

8.  Role of IgE receptors in effector function of human eosinophils.

Authors:  M Capron; H L Spiegelberg; L Prin; H Bennich; A E Butterworth; R J Pierce; M A Ouaissi; A Capron
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

9.  Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins.

Authors:  G G Wong; J S Witek; P A Temple; K M Wilkens; A C Leary; D P Luxenberg; S S Jones; E L Brown; R M Kay; E C Orr
Journal:  Science       Date:  1985-05-17       Impact factor: 47.728

10.  Co-culture of human lung-derived mast cells with mouse 3T3 fibroblasts: morphology and IgE-mediated release of histamine, prostaglandin D2, and leukotrienes.

Authors:  F Levi-Schaffer; K F Austen; J P Caulfield; A Hein; P M Gravallese; R L Stevens
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

View more
  71 in total

Review 1.  Regulation of expression of the 5-lipoxygenase pathway.

Authors:  T D Bigby
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 3.  Pathophysiological mechanisms of asthma. Application of cell and molecular biology techniques.

Authors:  K F Chung; I M Adcock
Journal:  Mol Biotechnol       Date:  2001-07       Impact factor: 2.695

4.  Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome.

Authors:  W F Owen; J Petersen; D M Sheff; R D Folkerth; R J Anderson; J M Corson; A L Sheffer; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C.

Authors:  S Arinaga; N Karimine; K Takamuku; S Nanbara; H Inoue; R Abe; D Watanabe; H Matsuoka; H Ueo; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8.

Authors:  Ho Jeong Na; Robert G Hamilton; Amy D Klion; Bruce S Bochner
Journal:  J Immunol Methods       Date:  2012-06-06       Impact factor: 2.303

Review 7.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

8.  Eosinophils altered phenotypically and primed by culture with granulocyte/macrophage colony-stimulating factor and 3T3 fibroblasts generate leukotriene C4 in response to FMLP.

Authors:  W F Owen; J Petersen; K F Austen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

9.  Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition.

Authors:  K Yasui; B Hu; T Nakazawa; K Agematsu; A Komiyama
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

10.  Transcriptional regulation of interleukin 3 gene expression in T lymphocytes.

Authors:  S G Shoemaker; R Hromas; K Kaushansky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.